Secondary infections and long-term outcomes among hospitalized elderly and non-elderly patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and treated with baricitinib: a comparative study from the national centre of Hungary.

Publication date: Feb 17, 2024

Baricitinib is considered a first-line treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected adult patients with an associated cytokine storm syndrome (CSS). Our objective was to compare rates of secondary infections and long-term outcomes of elderly and non-elderly patients who received baricitinib for COVID-19. We conducted a single-centre observational study between November 2020 and September 2023, focusing on hospitalized adult SARS-CoV-2 patients with CSS, categorized as elderly (≥ 65 years) and non-elderly (

Open Access PDF

Concepts Keywords
Elderly Baricitinib
Hungary Coronavirus disease 2019
Infections COVID-19
November Elderly
Secondary infection


Type Source Name
disease MESH Secondary infections
disease VO Severe acute respiratory syndrome coronavirus 2
drug DRUGBANK Baricitinib
disease MESH cytokine storm syndrome
disease MESH COVID-19
disease MESH syndrome
drug DRUGBANK Aminolevulinic acid
drug DRUGBANK Trestolone
disease MESH severe acute respiratory syndrome
disease MESH complications
drug DRUGBANK Coenzyme M
disease IDO secondary infection
disease MESH clinical course
drug DRUGBANK Angiotensin II
disease MESH Infectious Diseases
disease VO time
disease VO organization
drug DRUGBANK Oxygen
disease MESH opportunistic infections
drug DRUGBANK Acyclovir
disease MESH nosocomial infections
disease MESH infections
drug DRUGBANK Piroxicam
drug DRUGBANK Tocilizumab
disease MESH emergency
disease VO vaccine
disease VO Sputnik V
disease VO vaccination
disease VO dose
disease IDO blood
disease IDO cell
disease MESH pneumonitis
drug DRUGBANK Medical air
disease VO organ
disease MESH acute respiratory distress syndrome
disease MESH shock
disease VO URE
disease MESH acute renal failure
disease MESH pancytopenia
disease MESH delirium
drug DRUGBANK Favipiravir
drug DRUGBANK Dexamethasone
drug DRUGBANK Heparin
drug DRUGBANK L-Alanine
disease IDO symptom
disease IDO infection
disease IDO organism
disease MESH death
disease MESH essential hypertension
disease MESH Diabetes mellitus
disease MESH malignancy
disease MESH hematologic malignancy
drug DRUGBANK Ethanol
disease MESH Obesity
disease VO vaccinated
disease VO adverse event
disease MESH cardiovascular disease
disease MESH chronic renal disease
disease MESH cerebrovascular disease
disease MESH morbidity
disease MESH chronic illnesses
disease MESH inflammation
disease IDO production
disease MESH lymphopenia
pathway KEGG Cellular senescence
disease MESH Bloodstream infections
disease MESH pulmonary aspergillosis
disease MESH Hospital acquired pneumonia
disease MESH Intraabdominal infection
disease MESH soft tissue infection
disease MESH Urinary tract infection
disease MESH blepharitis
disease MESH bronchitis
disease MESH gastroenteritis
disease MESH keratitis
disease MESH otitis externa
disease MESH otitis media
disease MESH prostatitis
disease MESH enterocolitis
disease MESH Herpes simplex
disease VO population
disease MESH thrombosis
disease MESH fibrosis
disease MESH multiple organ failure
disease MESH dysbiosis
drug DRUGBANK Water
drug DRUGBANK Isoxaflutole
disease MESH drug interactions
disease MESH drug induced liver injury
disease MESH neutropenia
drug DRUGBANK Creatinine
disease VO Optaflu
disease MESH influenza
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease MESH upper respiratory tract infections
disease MESH cellulitis
drug DRUGBANK Zolmitriptan
disease VO protocol
drug DRUGBANK Hexocyclium
drug DRUGBANK Esomeprazole
disease MESH viral infections
disease VO age
disease MESH maedi
disease MESH arthritis

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *